Combination Therapy Study for Unfit Patients with Hodgkin Lymphoma

The chapter presents the findings of a study on the safety and efficacy of combining Brentuximab vedotin with either dacarbazine or nivolumab in older, previously untreated classical Hodgkin lymphoma patients who are unfit for traditional chemotherapy. Results indicate high response rates, durable efficacy, and manageable toxicity levels, offering a potential alternative to standard chemotherapy for some patients.